BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen SH, Xu LY, Wu YP, Ke ZB, Huang P, Lin F, Li XD, Xue XY, Wei Y, Zheng QS, Xu N. Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma. BMC Cancer 2021;21:79. [PMID: 33468079 DOI: 10.1186/s12885-021-07795-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Ma W, Zhang F, Huang H, Wang W, Zhu Y, Lu Y, Guo H, Gan W. Contrast-Enhanced Ultrasound Features of Adult Xp11.2 Translocation Renal Cell Carcinoma: Differential Diagnosis With Three Main Renal Cell Carcinoma Subtypes. J Ultrasound Med 2022. [PMID: 35103338 DOI: 10.1002/jum.15951] [Reference Citation Analysis]
2 Baheen Q, Liu Z, Hao Y, Sawh RRR, Li Y, Zhao X, Hong P, Wu Z, Ma L. The Significant Role of Tumor Volume on the Surgical Approach Choice, Surgical Complexity, and Postoperative Complications in Renal Cell Carcinoma With Venous Tumor Thrombus From a Large Chinese Center Experience. Front Oncol 2022;12:869891. [DOI: 10.3389/fonc.2022.869891] [Reference Citation Analysis]
3 Temiz MZ. Commentary: Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:730782. [PMID: 34676165 DOI: 10.3389/fonc.2021.730782] [Reference Citation Analysis]
4 Lee M, Lee Y, Huang S, Chang C, Ko C, Lee W, Chen T, Tzou S, Huang C, Tai M, Lin Y, Kung M, Tsai M, Chen Y, Chang Y, Wen Z, Huang C, Chu T. DLK2 Acts as a Potential Prognostic Biomarker for Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis. Genes 2022;13:629. [DOI: 10.3390/genes13040629] [Reference Citation Analysis]
5 Davis L, Recktenwald M, Hutt E, Fuller S, Briggs M, Goel A, Daringer N. Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy. Cancers (Basel) 2022;14:1259. [PMID: 35267567 DOI: 10.3390/cancers14051259] [Reference Citation Analysis]